JPH11509844A5 - - Google Patents

Info

Publication number
JPH11509844A5
JPH11509844A5 JP1997506964A JP50696497A JPH11509844A5 JP H11509844 A5 JPH11509844 A5 JP H11509844A5 JP 1997506964 A JP1997506964 A JP 1997506964A JP 50696497 A JP50696497 A JP 50696497A JP H11509844 A5 JPH11509844 A5 JP H11509844A5
Authority
JP
Japan
Prior art keywords
nmda
sulfate
response
5β3βs
5β3αs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997506964A
Other languages
English (en)
Japanese (ja)
Other versions
JP4313435B2 (ja
JPH11509844A (ja
Filing date
Publication date
Priority claimed from US08/559,442 external-priority patent/US5888996A/en
Application filed filed Critical
Priority claimed from PCT/US1996/012198 external-priority patent/WO1997003677A1/en
Publication of JPH11509844A publication Critical patent/JPH11509844A/ja
Publication of JPH11509844A5 publication Critical patent/JPH11509844A5/ja
Application granted granted Critical
Publication of JP4313435B2 publication Critical patent/JP4313435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50696497A 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 Expired - Fee Related JP4313435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US143995P 1995-07-24 1995-07-24
US60/001,439 1995-07-24
US50775795A 1995-07-26 1995-07-26
US08/507,757 1995-07-26
US08/559,442 1995-11-15
US08/559,442 US5888996A (en) 1995-07-26 1995-11-15 Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
PCT/US1996/012198 WO1997003677A1 (en) 1995-07-24 1996-07-24 Inhibition of nmda receptor activity by pregnenolone sulfate derivatives

Publications (3)

Publication Number Publication Date
JPH11509844A JPH11509844A (ja) 1999-08-31
JPH11509844A5 true JPH11509844A5 (enExample) 2009-05-07
JP4313435B2 JP4313435B2 (ja) 2009-08-12

Family

ID=27356924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50696497A Expired - Fee Related JP4313435B2 (ja) 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制

Country Status (4)

Country Link
US (1) US6083941A (enExample)
EP (1) EP0840612A1 (enExample)
JP (1) JP4313435B2 (enExample)
WO (1) WO1997003677A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051599A1 (en) * 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
ES2288028T3 (es) * 1998-11-10 2007-12-16 Curamentis Ltd. Uso de agonistas de los receptores de glucocorticosteroides y/o mineralocorticosteroides, especialmente corticosteroides para el tratamiento de la drogadiccion.
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6623933B1 (en) 1999-08-31 2003-09-23 Trustees Of Boston University Methods for identifying a subunit specific modulator of N-methyl-D-asparate receptor
US20040204490A1 (en) * 1999-08-31 2004-10-14 Farb David H. Effect of steroids on NMDA receptors depends on subunit composition
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
WO2002036128A1 (en) * 2000-11-06 2002-05-10 Trustees Of Boston University Neuroactive steroid derivatives and methods of use
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
US7790404B2 (en) * 2001-08-20 2010-09-07 Sanford-Burnham Medical Research Institute Excitatory glycine receptors and methods
AUPR731901A0 (en) * 2001-08-28 2001-09-20 Goodchild, Colin Stanley Method of treatment
FR2850023B1 (fr) * 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
DE602004030103D1 (de) * 2003-04-18 2010-12-30 Advanced Medicine Res Inst Mittel zur behanldung von krankheiten zur aufbringung auf das auge
AU2004294714B2 (en) * 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
MXPA06007852A (es) * 2004-01-15 2007-01-31 Warner Chilcott Co Inc Profarmacos di-esteroidales de estradiol.
CN1906207A (zh) * 2004-01-15 2007-01-31 沃纳奇尔科特公司 乙炔雌二醇的二－甾族前体药物
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
JP2007532607A (ja) 2004-04-16 2007-11-15 シュバルツ　ファルマ　アクチェンゲゼルシャフト 慢性頭痛の予防及び治療のためのペプチド化合物の使用
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
ATE471717T1 (de) * 2004-08-27 2010-07-15 Ucb Pharma Gmbh Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US7795241B2 (en) * 2005-07-12 2010-09-14 Warner Chilcott Company, Llc Derivative prodrugs of ethinyl estradiol
WO2007008474A2 (en) * 2005-07-12 2007-01-18 Warner Chilcott Company, Inc. 3 -ester prodrugs of estradiol
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
JP4382735B2 (ja) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
RU2430737C2 (ru) * 2005-10-28 2011-10-10 Сон-Ю КИМ Экстракт семейства диоскорейных (dioscoreaceae) и содержащая его композиция для профилактики или лечения периферической невропатии
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20090203658A1 (en) * 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
EP2170334B1 (en) 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
CA2783331A1 (en) * 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Center Pregnenolone sulfate for the treatment of neurologic disorders
JP6205362B2 (ja) * 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
DK2806877T3 (da) 2012-01-23 2019-11-04 Sage Therapeutics Inc Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin
FR2992645B1 (fr) * 2012-07-02 2014-08-01 Univ Claude Bernard Lyon Nouveaux derives de pyrrolidine
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
CZ2014575A3 (cs) * 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
SMT202100226T1 (it) 2015-07-06 2021-05-07 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055263T2 (hu) * 2016-07-07 2021-11-29 Sage Therapeutics Inc 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
ES3038660T3 (en) 2016-10-18 2025-10-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
CN119350419A (zh) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP3988096A1 (en) * 2020-10-26 2022-04-27 Universidad Pablo de Olavide OTRI Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
CA2118938A1 (en) * 1991-09-13 1993-04-01 Kelvin W. Gee Novel gabaa receptor with steroid binding sites
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf

Similar Documents

Publication Publication Date Title
US6083941A (en) Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives
JPH11509844A5 (enExample)
US5888996A (en) Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
CN104257657B (zh) 用于治疗cmt和相关疾病的治疗方法
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
EA007287B1 (ru) Усилители гамк при лечении заболеваний, связанных со сниженной активностью нейростероидов
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
Bakshi et al. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats
WO2016134257A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US8541395B2 (en) Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
Sadri‐Vakili et al. Inhibition of NMDA‐induced striatal dopamine release and behavioral activation by the neuroactive steroid 3α‐hydroxy‐5β‐pregnan‐20‐one hemisuccinate
US20110136769A1 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2024103012A1 (en) Polycyclic compounds for use in neurodegenerative conditions
EP1944041A1 (en) Therapeutic agent for neurogenic pain
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用
Butler Effects of corticosterone and ethanol co-exposure on hippocampal toxicity: Potential role for the NMDA NR2B subunit